1. Although the authors decide that 1200 patients will be enrolled, they do not rationally explain why 1200 patients will be required. This reviewer thinks that they should do power analysis to determine the number of patients.
2. Volatile anaesthetics enhance pro-oncogenic cellular signaling and increase the expression of pro-oncogenic protein markers (Oncotarget 2016; 7: 26042-56, Transl Res 2015; 166: 674-82) . Although these may occur with more than 1 MAC volatile anaesthetics (Anesthesiology 2006; 105: 1211-9) , remifentanil that is used more often that fentanyl in recent general anaesthesia management can reduce volatile anaesthetic concentration (Korean J Anesthesiol 2012; 63: 25-9) . Thus, as we generally use around 0.7 MAC volatile anaesthetics (at least less than 1 MAC) with remifentanil infusion, this low volatile anaesthetic concentration may not clinically detect their aggravating effects on cancer recurrence and metastasis. bmjopen-2017-018607 comments for the authors the manuscript describes a proposed study addressing two areas which are both timely and important. Specifically, retrospective/database data suggest that cancer outcome might be influenced by choice of anaesthesia and separately, delirium is increasingly identified as a herald of further adverse events in the post-operative period. Page numbers below refer to the BMJ open PDF page numbers and not the original page numbers on the word document generated by the authors • page 7, why do you restrict the age of the patients to 90 years? We live in an increasingly ageing society and it would seem relevant to include all of them. In particular, cognitive impairment is present most likely in the oldest patients and therefore the impact may be of the greatest interest.
REVIEWER
• The recognition that it is difficult (but deftly not impossible) to blind when the patient is receiving intravenous or inhalational anaesthesia is reasonable. In particular, efforts to achieve blinding (covering syringe pumps, masking monitor screens et cetera) which have been described are likely to jeopardise patients by introducing extra risk. The design is therefore appropriate.
• General. The introduction is very long and can easily be substantially shortened.
• Long-term survival. You have put the study period as being three years.
This is reasonable and if there is a meaningful difference you're likely to see it by that time. Nevertheless you will I'm sure wish to follow-up your patients for longer than that and I suggest that in your ethical application and perhaps as the later amendment to your protocol you allow yourself the possibility of much longer follow-up as well (five years or seven years,…).
• Power calculation. The delirium sample size calculation seems appropriate. I think that the effect size you are proposing (reduction from 30% to 20% in three year mortality) is probably more than you might expect to see. Therefore for the cancer survivor outcome you will need a larger sample size. Nevertheless, if you stick to the numbers driven by the calculation for dementia you will end up with a decent number to evaluate the outcome associated with cancer.
• Baseline. One of the contemporary key questions studies of delirium/cognitive function after surgery relates to the condition of the patient before the operation. Not just their position at baseline (i.e. what you measure with a thorough examination shortly before surgery) but rather what trajectory they were on. To access this it is necessary to get to the patient at an earlier time point. Sometimes this this is possible (if there is a period of radiotherapy for example) or for other reasons associated with surgery I think it be very interesting to consider measure of cognitive performance before the immediate preoperative value. This would help you to tackle the current hypothesis that what happens to patients immediate after surgery may in some partly driven by the trajectory that they were on beforehand. I suspect that this will not be possible for all of (or perhaps not even for many of) your patients but even if you could evaluate a subset in this way you would be enriching your study.
• Bispectral Index. I note that you are recording Bispectral Index and presumably you will also have end-tidal concentration of volatile anaesthetic agent as well as the infusion profile of propofol. There is a literature challenging whether excessive depth of anaesthesia is associated with poor outcome after surgery. You might consider ensuring that the information you collect on the BIS and the anaesthetic administration is sufficient for you to have a look at this in your post-hoc analysis.
• There is a literature describing possible effects of narcotics on cancer cells. In this area morphine would seem to be different from other members of the fentanyl series. Specifically, morphine promotes angiogenesis. You might consider trying to standardise on only morphine or on only sufentanil. Alternatively, might want to be prepared to analyse against this after the study is finished.
• Exclusions. A proportion of patients will not agree to be randomised. You might consider asking them if they are nevertheless willing to be followed up. In that case you could record the anaesthetic that they were given and follow them up as one or more parallel groups alongside the other randomised groups.
• Interim analysis. This is a very large study and a significant investment of people and time. Consider discussing with the statistician whether an interim analysis would be useful • safety committee. Do you have a supervising safety committee to keep an eye on the patient population as they progress through the study? (BMJ 2011; 342: d1491) performed randomised trial to determine effects of perioperative epidural analgesia on cancer and recurrence-free survival, they found that epidural analgesia was not associated with improved cancer-free survival. As there is still a lack of robust data that total intravenous anaesthesia may improve postoperative delirium and long-term survival particularly in elderly patients undergoing cancer surgery, this reviewer believes that this multicenter, open-label, randomized controlled trial may be valuable. However, this reviewer has the following concerns.
Comment 1: Although the authors decide that 1200 patients will be enrolled, they do not rationally explain why 1200 patients will be required. This reviewer thinks that they should do power analysis to determine the number of patients.
Response: Excellent comments. We did two power calculations. 1) Delirium reduction (early outcome), the sample size required to detect differences was 1106 patients. Taking into account a loss-to-follow-up rate of about 6%, we need to enroll 1177 patients. 2) Long-term survival improvement (long-term outcome), the sample size required to detect differences was 588 patients. Taking into account a loss-to-follow-up rate of about 20%, we need to enroll 735 patients. After considering the two calculated sample size, we plan to enroll 1200 patients in the present study. Detailed description of sample size calculation was provided in the part of "Sample size calculation" (page 12, line 10 to page 13, line 12).
Comment 2: Volatile anaesthetics enhance pro-oncogenic cellular signaling and increase the expression of pro-oncogenic protein markers (Oncotarget 2016; 7: 26042-56, Transl Res 2015; 166: 674-82) . Although these may occur with more than 1 MAC volatile anaesthetics (Anesthesiology 2006; 105: 1211-9) , remifentanil that is used more often that fentanyl in recent general anaesthesia management can reduce volatile anaesthetic concentration (Korean J Anesthesiol 2012; 63: 25-9). Thus, as we generally use around 0.7 MAC volatile anaesthetics (at least less than 1 MAC) with remifentanil infusion, this low volatile anaesthetic concentration may not clinically detect their aggravating effects on cancer recurrence and metastasis.
Response: It is true that the widespread use of short-acting opioids (such as remifentanil) lowers the concentration of inhaled volatile anesthetics during anesthesia. Theoretically, this may decrease the unfavorable pro-oncogenic effects of volatile anesthetics. However, the purpose of the present study is to investigate the effects of anesthesia currently being used in clinical practice. During the study period, we also collected data such as concentration of inhaled sevoflurane. In fact, the concentration of inhaled sevoflurane varies from 2 to 3% (MAC from 0.8 to 1.1) in most of the patients in the sevoflurane group. the manuscript describes a proposed study addressing two areas which are both timely and important. Specifically, retrospective/database data suggest that cancer outcome might be influenced by choice of anaesthesia and separately, delirium is increasingly identified as a herald of further adverse events in the post-operative period. Page numbers below refer to the BMJ open PDF page numbers and not the original page numbers on the word document generated by the authors Comment: page 7, why do you restrict the age of the patients to 90 years? We live in an increasingly ageing society and it would seem relevant to include all of them. In particular, cognitive impairment is present most likely in the oldest patients and therefore the impact may be of the greatest interest.
Reviewer 2
Response: It is true that the risk of complications (including cognitive impairment) is higher in the oldest ones. In the present study, we excluded patients with age ≥ 90 years because of the following considerations. Firstly, patients with age ≥ 90 years constitute a small part of our patients during daily practice. Secondly, according to our clinical experience patients with age ≥ 90 years are more frequently comorbid with problems such as hearing or vision disability, or dementia, which impede them to complete pre-and postoperative assessments. Therefore, we restrict the age of the patients to 90 years.
Comment: The recognition that it is difficult (but deftly not impossible) to blind when the patient is receiving intravenous or inhalational anaesthesia is reasonable. In particular, efforts to achieve blinding (covering syringe pumps, masking monitor screens et cetera) which have been described are likely to jeopardise patients by introducing extra risk. The design is therefore appropriate.
Response: Thank you.
Comment: General. The introduction is very long and can easily be substantially shortened.
Response: We have revised and shortened the introduction.
Comment: Long-term survival. You have put the study period as being three years. This is reasonable and if there is a meaningful difference you're likely to see it by that time. Nevertheless you will I'm sure wish to follow-up your patients for longer than that and I suggest that in your ethical application and perhaps as the later amendment to your protocol you allow yourself the possibility of much longer follow-up as well (five years or seven years,…).
Response: Yes. We will follow up our patients for longer durations if we find meaningful differences between groups at 3-year follow-up. We will apply for ethics approval for amendment to the protocol.
Comment: Power calculation. The delirium sample size calculation seems appropriate. I think that the effect size you are proposing (reduction from 30% to 20% in three year mortality) is probably more than you might expect to see. Therefore for the cancer survivor outcome you will need a larger sample size. Nevertheless, if you stick to the numbers driven by the calculation for dementia you will end up with a decent number to evaluate the outcome associated with cancer.
Response: Agree with you that the proposed long-term effect (i.e., a reduction of mortality from 30% to 20%) is probably more than we might expect to see. Since the calculated sample size for delirium is much larger than that for 3-year survival, we chose the number calculated for delirium.
Comment: Baseline. One of the contemporary key questions studies of delirium/cognitive function after surgery relates to the condition of the patient before the operation. Not just their position at baseline (i.e. what you measure with a thorough examination shortly before surgery) but rather what trajectory they were on. To access this it is necessary to get to the patient at an earlier time point. Sometimes this this is possible (if there is a period of radiotherapy for example) or for other reasons associated with surgery I think it be very interesting to consider measure of cognitive performance before the immediate preoperative value. This would help you to tackle the current hypothesis that what happens to patients immediate after surgery may in some partly driven by the trajectory that they were on beforehand. I suspect that this will not be possible for all of (or perhaps not even for many of) your patients but even if you could evaluate a subset in this way you would be enriching your study.
Response: Thank you for your suggestions. In the present study, we will evaluate MMSE and assess delirium shortly before surgery. These results will help us to observe changes after surgery. However, we do not have opportunity to get to the patients earlier.
Comment: Bispectral Index. I note that you are recording Bispectral Index and presumably you will also have end-tidal concentration of volatile anaesthetic agent as well as the infusion profile of propofol. There is a literature challenging whether excessive depth of anaesthesia is associated with poor outcome after surgery. You might consider ensuring that the information you collect on the BIS and the anaesthetic administration is sufficient for you to have a look at this in your post-hoc analysis.
Response: Yes. We hope to do some post-hoc analysis with the collected data.
Comment: There is a literature describing possible effects of narcotics on cancer cells. In this area morphine would seem to be different from other members of the fentanyl series. Specifically, morphine promotes angiogenesis. You might consider trying to standardise on only morphine or on only sufentanil. Alternatively, might want to be prepared to analyse against this after the study is finished.
Response: Since there are 17 centers in this study and each center has its own habit, we accepted postoperative analgesia with either morphine or sufentanil after discussion. We might be able to analyze the differences between morphine and sufentanil after the study is finished.
Comment: Exclusions. A proportion of patients will not agree to be randomised. You might consider asking them if they are nevertheless willing to be followed up. In that case you could record the anaesthetic that they were given and follow them up as one or more parallel groups alongside the other randomised groups.
Response: In the present study, we do not plan to follow up patients who do not provide consent. But we will consider your suggestion in our future studies.
Comment: Interim analysis. This is a very large study and a significant investment of people and time.
Consider discussing with the statistician whether an interim analysis would be useful
Response: We discussed this problem with statistician. Considering the fact that both inhalational and intravenous general anaesthesia are routinely performed in daily practice and no additional risk is produced to participants, we did not plan interim analysis. This also simplifies the study design.
Comment: Safety committee. Do you have a supervising safety committee to keep an eye on the patient population as they progress through the study?
Response: In the present study, the Ethics Committee of each participating center will supervise the safety outcomes. The conduct of the study and safety problems will be reported to the Ethics Committee regularly. Severe adverse events will be reported to the Ethics Committee as soon as possible. And, in case of severe adverse events, the relationship with the study design will be evaluated. Study-related severe adverse events will lead to temporary stop of the study. Restart of the study will be decided by the Ethics Committee.
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